Mendus Q1 2023: Opportunities and hurdles - Redeye

Redeye provides its comment on Mendus’ Q1 2023 report. We believe the company has a solid plan for continued clinical development of vididencel and ilixadencel. However, uncertainties around financing these trials cast a shadow over the investment case.

Länk till analysen i sin helhet: https://www.redeye.se/research/906964/mendus-q1-2023-opportunities-and-hurdles?utm_source=finwire&utm_medium=RSS